{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063938","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.305500+00:00","generated_at":"2026-05-22T12:45:55.852223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts","bullets":["Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.","Net loss of $72.2M in Q1 2025; R&D expenses $70.9M (down from $140.2M Q4 2024 incl. one-time $75M license payment).","Over 300 patients enrolled in darovasertib + crizotinib 1L MUM registrational trial; median PFS readout targeted by YE 2025.","FDA Breakthrough Therapy designation for neoadjuvant darovasertib in primary UM; Phase 3 design finalized after Type D meeting.","Three IND filings targeted in 2025: PRMT5 (IDE892), B7H3/PTK7 ADC (IDE034), KAT6/7 (IDE574); IDE849 Phase 1 started in US."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063938","json":"https://secwatch.observer/filing/0000950170-25-063938.json","markdown":"https://secwatch.observer/filing/0000950170-25-063938.md","text":"https://secwatch.observer/filing/0000950170-25-063938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/0000950170-25-063938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:45:55.852223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}